Optimal duration of neoadjuvant androgen withdrawal therapy before radical prostatectomy in clinically confined prostate cancer

Seminars in Urologic Oncology

Volumn 14, Issue 2 SUPPL. 2, 1996, Pages 39-47

  Gleave, M E ^a   Goldenberg, S L ^a   Jones, E C ^a   Bruchovsky, N ^a   Kinahan, J ^a   Sullivan, L D ^a  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

androgen withdrawal therapy; Prostate cancer; radical prostatectomy

Indexed keywords

CYPROTERONE ACETATE; DIETHYLSTILBESTROL; FLUTAMIDE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TRIPTORELIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TREATMENT OUTCOME;

ADULT; AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0029937525     PISSN: 10810943     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)